Natixis Seagen Inc. Transaction History

Natixis

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $83.1 Million - $93.8 Million	433,940 Added 798.01%	488,318 $104 Million
Q2 2023 Aug 11, 2023	BUY	$187.64 - $206.25 $9.42 Million - $10.4 Million	50,218 Added 1207.16%	54,378 $10.5 Million
Q1 2023 May 12, 2023	SELL	$127.59 - $203.08 $2.86 Million - $4.56 Million	-22,448 Reduced 84.37%	4,160 $842,000
Q4 2022 Feb 24, 2023	SELL	$117.37 - $139.17 $16.6 Million - $19.7 Million	-141,232 Reduced 84.15%	26,608 $3.42 Million
Q4 2022 Feb 13, 2023	BUY	$117.37 - $139.17 $19.1 Million - $22.6 Million	162,479 Added 3030.76%	167,840 $21.6 Million
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $436,245 - $580,854	-3,225 Reduced 37.56%	5,361 $734,000
Q2 2022 Aug 12, 2022	BUY	$108.81 - $179.33 $645,460 - $1.06 Million	5,932 Added 223.51%	8,586 $1.52 Million
Q1 2022 May 13, 2022	SELL	$119.61 - $157.85 $131,690 - $173,792	-1,101 Reduced 29.32%	2,654 $382,000
Q4 2021 Feb 14, 2022	SELL	$142.57 - $190.86 $60,307 - $80,733	-423 Reduced 10.12%	3,755 $581,000
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $595,156 - $709,507	4,178 New	4,178 $709,000
Q2 2021 Aug 13, 2021	SELL	$135.08 - $161.1 $6.99 Million - $8.34 Million	-51,760 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$137.51 - $190.8 $1.98 Million - $2.74 Million	-14,373 Reduced 21.73%	51,760 $7.19 Million
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $10.9 Million - $14 Million	66,133 New	66,133 $11.6 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.